Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regar...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/7/e002835.full |
id |
doaj-6cf348571459444c958d6348f9940c7d |
---|---|
record_format |
Article |
spelling |
doaj-6cf348571459444c958d6348f9940c7d2021-08-04T16:30:44ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-07-019710.1136/jitc-2021-002835Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitorsSamra Turajlic0Igor Puzanov1Paul C Lorigan2Benjamin Switzer3Renal and Skin Units, Royal Marsden NHS Foundation Trust, London, UKDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USADivision of Cancer Sciences, The University of Manchester, Manchester, UKDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USAThe clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.https://jitc.bmj.com/content/9/7/e002835.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Samra Turajlic Igor Puzanov Paul C Lorigan Benjamin Switzer |
spellingShingle |
Samra Turajlic Igor Puzanov Paul C Lorigan Benjamin Switzer Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors Journal for ImmunoTherapy of Cancer |
author_facet |
Samra Turajlic Igor Puzanov Paul C Lorigan Benjamin Switzer |
author_sort |
Samra Turajlic |
title |
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors |
title_short |
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors |
title_full |
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors |
title_fullStr |
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors |
title_full_unstemmed |
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors |
title_sort |
clinical and immunologic implications of covid-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2021-07-01 |
description |
The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed. |
url |
https://jitc.bmj.com/content/9/7/e002835.full |
work_keys_str_mv |
AT samraturajlic clinicalandimmunologicimplicationsofcovid19inpatientswithmelanomaandrenalcellcarcinomareceivingimmunecheckpointinhibitors AT igorpuzanov clinicalandimmunologicimplicationsofcovid19inpatientswithmelanomaandrenalcellcarcinomareceivingimmunecheckpointinhibitors AT paulclorigan clinicalandimmunologicimplicationsofcovid19inpatientswithmelanomaandrenalcellcarcinomareceivingimmunecheckpointinhibitors AT benjaminswitzer clinicalandimmunologicimplicationsofcovid19inpatientswithmelanomaandrenalcellcarcinomareceivingimmunecheckpointinhibitors |
_version_ |
1721222182380503040 |